Lates News
Boston - (U.S. Business Information) - September 24, 2025 - PepGen Inc. (NASDAQ: PEPG) is a clinical-stage biotechnology company developing next-generation oligonucleotide therapies aimed at changing the treatment of severe neuromuscular and neurological diseases. The company announced today positive clinical data from the 15 mg/kg dose cohort of the ongoing FREEDOM-DM1 Phase 1 Single Ascending Dose (SAD) study in patients with myotonic dystrophy (DM1). These latest results show that the average splicing correction rate after a single dose of 15 mg/kg of PGN-EDODM1 is 53.7%, significantly higher than previously reported splicing correction in DM1 patients.
Latest